Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ardelyx, Inc. (ARDX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1400+0.2779 (+32.24%)
At close: 04:00PM EST
1.2200 +0.08 (+7.02%)
After hours: 07:59PM EST
Advertisement

Ardelyx, Inc.

34175 Ardenwood Boulevard
Fremont, CA 94555
United States
510 745 1700
http://www.ardelyx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees129

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael G. RaabPres, CEO & Director947.66kN/A1965
Mr. Justin A. Renz CPA, MST, M.S.T., MBACFO & Chief Accounting Officer394.74kN/A1972
Ms. Susan RodriguezChief Commercial Officer588.96kN/A1964
Mr. Jeffrey W. JacobsChief Scientific OfficerN/AN/A1963
Ms. Elizabeth A. GrammerChief Legal & Admin. Officer and Sec.N/AN/A1964
Ms. Kimia KeshtbodMang. of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Sarah O'BrienChief People OfficerN/AN/AN/A
Mr. David P. RosenbaumChief Devel. OfficerN/AN/A1961
Mr. Robert C. BlanksChief Regulatory Affairs & Quality Assurance OfficerN/AN/A1960
Ms. Karen HarriganSr. Director Market Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.

Corporate Governance

Ardelyx, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 9. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement